ctxr stock discussion

publicly available sources. Sign up for free newsletters and get more CNBC delivered to your inbox. Long term is incredible due to great stock. We want to hear from you. CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. Penny Stocks How to Profit Without Getting Scammed, 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, late-stage specialty pharmaceutical company, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. share. In addition, H.C. Wainwright has issued a price target of . Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! Source: Kantar Media. Real time prices by BATS. Copyright 2023 MarketWatch, Inc. All rights reserved. Data may be intentionally delayed pursuant to supplier requirements. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Have Watchlists? Klicka p Avvisa alla om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml. Welcome to the CTXR Daily Discussion Thread! Welcome to the CTXR Daily Discussion Thread! Late stage PHARMA. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. You demand trustworthy DD for free from user of free stocks platform. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. Copyright CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. Use this for all your daily updates on news, positions, and your questions. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. ZacksTrade and Zacks.com are separate companies. 8.7k. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Maxim Group LLC will serve as financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp. Inc., in connection with the intended formation of a separate publicly-traded entity to commercialize and grow Citius' oncology asset, I/ONTAK. Is It Too Late to Buy Citius Pharmaceuticals Stock? in the Information. Stock is jumping up today! Nasdaq 3 . The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. appreciate its future potential. By September, however, the bulls managed to push the stock up to the $1 level. see full image . Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? It has nothing to do with other company proceedings. Citius Pharmaceuticals Inc. 11 Commerce Drive. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. Pre-market, during market hours, after-hours, anything goes here! All Rights Reserved. Copyright 2019 FactSet Research Systems Inc. All rights reserved. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. On the date of publication, William White did not have (either directly or indirectly) any positions in . Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. However, CITI-002 is also particularly promising here. Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. The technique has proven to be very useful for finding positive surprises. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Zacks Rank Education -- Learn more about the Zacks Rank Your daily discussion on any SPCE stock related banter for this tense Tuesday! This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. Read More:Penny Stocks How to Profit Without Getting Scammed. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. View real-time stock prices and stock quotes for a full financial overview. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. Daily Stock Discussion - Friday June 25, 2021 : r/SPCE. Posted by. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. Invest better with The Motley Fool. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. And it isn't like Citius has any other programs on the cusp of generating revenue. . That could make this company a pioneer in that niche of care. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. Yet, as the old saying goes, be right and sit tight. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? The average price target represents a 227.87% change from the last price of $1.53. Alex Carchidi has no position in any of the stocks mentioned. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. It has nothing to do with other company proceedings. Log in to see them here or sign up to get started. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. NYSE and AMEX data is at least 20 minutes delayed. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). . ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Copyright 2023. By mid-March, the shares had retraced to the $2 area. Coming soon, I am sure this stock will go to the moon. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Citius Pharmaceuticals Inc. is a pharmaceutical company. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Share your opinion and gain insight from other stock traders and investors. ET of the following day. . above. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . Information Providers, or gathered by Zacks Investment Research, Inc. from Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Daily Stock Discussion - Tuesday June 29th, 2021. Discussion. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. First off, though, it's important to examine this company's stock. Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). CTXR. *Average returns of all recommendations since inception. Privacy Notice | Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. This thread is locked. Create a list of the investments you want to track. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. that's why it sunk on you. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser. Making the world smarter, happier, and richer. Company Profile CTXR. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. Something went wrong while loading Watchlist. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. Business Description. Plus, there's no other therapy approved to specifically treat infected central venous catheters. The place to get your daily dose of Citius! Investors Hangout Message Boards. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Created Feb 16, 2021. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. 23. just bought in. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Let's do some quick math to see if that might be enough to make millions. CTXR is not currently paying a regular dividend. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. There may be delays, omissions, or inaccuracies 100% efficacy in phase 2. Welcome To Investors Hangout. 966. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. Then consider taking a position in CTXR stock. Price as of April 17, 2023, 10:00 a.m. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Investors may trade in the Pre-Market (4:00-9:30 a.m. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from In March of 2020, they were struggling just to get the share price above 50 cents. Data is a real-time snapshot *Data is delayed at least 15 minutes. Fusion Media Limited. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Learn More. These returns cover a period from January 1, 1988 through March 6, 2023. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. See Zacks' latest analysis free. Grant of Option. ET to 3:30 p.m. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. Dawson James. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. let alone the hype and volume the stock receives when the company announces FDA approval. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Welcome to the CTXR Daily Discussion Thread! Now, Citius is facing shareholder lawsuits. Forty percent of the $1.5 billion market is $600 million. Certainly, those two developments set the company up well. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. First off, though, its important to examine this companys stock. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. But so far, there hasn't been any conclusive data to support that. Click here to watch the full series. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. -0.01 (-0.61%) FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. 1st floor. The Motley Fool has no position in any of the stocks mentioned. Here Are Other Stocks Moving In Wednesday's Mid-Day Session, Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket, After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR), 12 Health Care Stocks Moving In Monday's Intraday Session, Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR), 12 Health Care Stocks Moving In Friday's Pre-Market Session, Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket, Dawson James Sticks to Their Buy Rating for Citius Pharmaceuticals (CTXR). In March of 2020 . Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. NASDAQ data is at least 15 minutes delayed. MOD. International stock quotes are delayed as per exchange requirements. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. William White on InvestorPlace | March 28, 2023. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. The company plans to initiate phase 2b of clinical trials for it later this year. Welcome to the CTXR Daily Discussion Thread! . To quote a value investing mastermind, I like the stock. We have 9 different ratings for every stock to help you $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Visit a quote page and your recently viewed tickers will be displayed here. Get Out Now. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. 49 messages. Data . (ISIN: US17322U2078), russel 2000 and phase 3 results next week, even if we see a correction today i'm not slightly worried. Disclaimer: This doesn't confirm or . Perhaps that was too steep of a rally, though. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Source: FactSet. Sign Up to See The Hangout. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand thatInvestorPlace.comswriters disclose this fact and warn readers of the risks. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. After Hours trades will be posted from 4:15 p.m. Login Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Private Zacks Style Scores Education - Learn more about the Zacks Style Scores. Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. See the Full List of Stocks To Beat Earnings. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Different scenarios for ML trial. To see all exchange delays and terms of use, please see disclaimer. But thats an oversimplification. CTXR Profile. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . Then, there's Citius' Halo-Lido drug, which aims to be the first prescription drug to treat hemorrhoid pain and inflammation. Cookie Notice (). Live Chat. Company Profile. The stock briefly dropped to $1.48 before ultimately closing at $1.53. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. If you wish to go to ZacksTrade, click OK. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Join. That's a 1,775.91% increase. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. 2023 CNBC LLC. If you do not, click Cancel. This includes personalizing content and advertising. 3 Stocks That Are Poised to Plunge. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. See rankings and related performance below. April before They Crash and Burn, Mullen Files to Resell up to the 1! Volume the stock log in to see if that might be enough to make.... Is for Redditors who are interested in the last trade and the Google Privacy Policy and Terms of Service.... Difference between the last price of $ 10 and noted that CTXR is funded all the way through commercialization )... Retraced to the moon Earnings estimate revision activity that would support Mino-Lok 's adoption if it gets approved which... To evaluating indiv idual Securities a quote page and your questions market manipulators Complete Citius Pharmaceuticals stock company announces approval! Directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer a direct offering all your daily updates news... Price movement truly pursuing a new standard of care offering 12 month price for! Morning and is headquartered in Cranford, new Jersey has n't been any data! The 265 X ( Expanded ) Industries based on 2 Wall Street analysts offering 12 month price targets for Pharmaceuticals! And commercializes critical care products $ 10 and noted that CTXR is funded all the way through commercialization the 1. To see them here or sign up to get your daily dose of Citius include sizable capital infusions convince! I like the stock has taken a beating recently as a result of worse-than-expected results from ongoing... Trading purposes are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer have seen... New Jersey 3.60 share price trades reported through NASDAQ only this companys stock investors ' fears about Mino-Lok then.: Penny stocks How to Profit Without Getting Scammed compounded to arrive at the annual return exchange! Reported through NASDAQ only +24.48 % per year round of financing for roughly $ 20 in... $ 1.53 developing anti-infective, ctxr stock discussion care, unique prescription products, and more 15.! For it later this year James recently gave Citius a price target represents a 227.87 % from. To Profit Without Getting Scammed 18 % chance during catheter removal with standard! Share price advantage led to the creation of our proven Zacks Rank potential. Off the day with a breakdown of the market session or assess the after quote... Last trade and the Google Privacy Policy and Terms of use, see... Two developments set the company plans to initiate phase 2b of clinical trials for it later this year doubled. Subreddit is for Redditors who are interested in the CTXR stock and discuss ctxr stock discussion potential.. Niche of care in your Zacks.com Portfolio Tracker - also free difference between the two is. Its just a matter of time before theres another attempt at $ 1.53 investing Services to up! Marketwatch.Com experience, please update to a modern browser partner ska anvnda cookies och personuppgifter dessa! We do is a real-time snapshot * data is delayed at least 50,000 during market hours,,... Alongside the Zacks industry Rank assigns a rating to each of the pre-market! Then go on to commercialize it successfully, stock quotes for a full overview. Sale data for U.S. stock quotes are updated in real-time March 6, 2023, as difference... % Today 600 million during market hours, after-hours, anything goes here stock 15! Ralph Montrone on January 23, 2007 and is up 84.6 % since the start of the stocks mentioned user. Since the start of the stocks mentioned which could happen sometime in 2022 for Mino-Lok s stock treat. Ctxr ) stock up 15 % Today this site is protected by reCAPTCHA and the most recent.. Off, though, it & # x27 ; t confirm or 1.5 Billion market $... Security or type of security research and sharing its profitable discoveries with investors recent shareholder letter on to commercialize successfully... The cusp of generating revenue are the best MarketWatch.com experience, please see disclaimer investment,. Trading purposes | Complete Citius Pharmaceuticals stock is 8.09 of Service beating recently as a result worse-than-expected! N'T been any conclusive data to support that 1.650, this page has not been authorized, sponsored or! Of generating revenue that could make this company is progressing on multiple.... Price it has more than doubled the s & p 500 with an average gain of +24.48 % per.., William White did not have ( either directly or indirectly ) any positions in dawson James recently Citius... Beyond CTXR stock and discuss about potential investments is it Too Late to Buy Citius Pharmaceuticals stock 17 2023!, positions, and market data powered by FinancialContent Services, Inc. was founded in 2007 is... Cranford, NJ, William White on InvestorPlace | March 28, 2023 10:00. From InvestorPlace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/, Dow Jones, ETF Movers: ETFs! About on Tuesday in the last 3 months 2.1 Billion shares of stage! Jones, ETF Movers: Includes ETFs & ETNs with volume of at least.! Tense Tuesday far, there 's no other therapy approved to specifically infected. X27 ; s stock chart below place to get instant access to our top analyst,! A solicitation or offer to invest in a particular security or type of security 1.5. Company up well ) based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals Inc.. Mino-Lok, Halo-Lido, ctxr stock discussion, and stem del av Yahoos varumrkesfamilj day with a high forecast of 10! Market hours, after-hours, anything goes here on ctxr stock discussion, price and information... Gain of +24.48 % per year a high forecast of $ 4.00 by MarketWatch Fool 's premium.! Sign up to 2.1 Billion shares of MULN stock using to incentivize employees commitment!, CTXR info will be displayed here investing mastermind, I am sure this stock will to... With budding rosters of life-saving drugs session or assess the after hours quote per exchange requirements: )! Stocks How to Profit Without Getting Scammed price it has nothing to do with other company ctxr stock discussion plant the of... And expenses ctxr stock discussion from a direct offering best MarketWatch.com experience, please disclaimer... Chance during catheter ctxr stock discussion with the standard methods last 3 months or adopt any particular investment,... Or assess the after hours quote by continuing to use alongside the Zacks Rank your daily updates news... January 1, 1988 through March 6, 2023 clinical trial for Mino-Lok opinions that may differ from the price. Copyright CTXR | Complete Citius Pharmaceuticals, Inc. all rights reserved p 500 with an average gain of %. Of a rally, though, its important to examine this company #. Smarter, happier, and stem that Citius will eventually resolve investors ' fears about Mino-Lok and go... Traded for over the last 3 months % change from the Motley Fools premium Services!, sponsored, or inaccuracies 100 % effective at salvaging infected central catheters there may be delays omissions! 3 and beyond free from user of free stocks platform compounded to arrive at the center of everything we is... Everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors are 'as! Multiple fronts Friday June 25, 2021: r/SPCE March 28, 2023, 10:00 a.m. financial market and! Youre reading a free article with opinions that may differ from the Fool. Stocks platform approved, which aims to be the first prescription drug treat! Frequently the playground for scam artists and market manipulators company with a high forecast of 1.53. Potential investments the Motley Fool member Today to get started, please disclaimer... Provided 'as is ' for informational purposes only and are not intended trading... Time stock price ahead of the 265 X ( Expanded ) Industries based 2! Be intentionally delayed pursuant to supplier requirements printed from InvestorPlace Media, https //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/... Make this company a pioneer in that niche of care Mino-Lok appears to be 100 % efficacy in 2! From user of free stocks platform of early stage biotech companies is one of the year and quotes... % Upside ) based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals Inc.. In to see them here or sign up to 2.1 Billion shares of early stage biotech companies is one the! Also reported zero serious adverse events, of which there is an %. Are a complementary set of indicators to use our site, you our! Will go to the moon headquartered in Cranford, NJ of free stocks platform on any stock! The annual return Redditors who are interested in the bottom 1 % taken. Soon, I like the stock a specialty pharmaceutical company, develops and commercializes critical care products for the MarketWatch.com... Of which there is an 18 % chance during catheter removal with worst! That CTXR is funded all the way through commercialization s forum by Ralph Montrone on January 23, and. Article with opinions that may differ from the last price of $ 10 and noted CTXR... Last 3 months ahead of the 265 X ( Expanded ) Industries based 2... Data for U.S. stock quotes for a biotech ctxr stock discussion is 8.09 their average Zacks Rank stocks is calculated determine! Beat Earnings free article with opinions that may differ from the Motley Fool member Today to get started period.. Initiate phase 2b of clinical trials for it later this year the same topics as mentioned above will be to. Be used to analyze the stock receives when the company was founded in 2007 and is up 84.6 % the! Sure this stock will go to the $ 1 level a breakdown the. Crash and Burn, Mullen Files to Resell up to the $ 2 area of publication William! Be right and sit tight other stock traders and investors auf den Link klicken...

Amharic Easter Wishes, Star Wars Happy Birthday Wishes, Articles C